EC Number |
Natural Substrates |
---|
3.4.15.1 | more |
AnCE is a single domain protein with ACE activity, an ACE homologue |
3.4.15.1 | angiotensin I + H2O |
angiotensin II is a vasoconstrictor that raises blood pressure and is formed from angiotensin I by the angiotensin I converting enzyme in the reninangiotensin system |
3.4.15.1 | amyloid beta-protein 1-42 + H2O |
angiotensin-converting enzyme converts amyloid beta-protein 1-42 to amyloid beta-protein1-40. ACE regulates Abeta1-42/Abeta1-40 ratio in vivo by converting secreted Abeta1-42 to Abeta1-40 and degrading Abetas.The upregulation of ACE activity can be a novel therapeutic strategy for Alzheimers disease |
3.4.15.1 | amyloid beta-protein 1-42 + H2O |
angiotensin-converting enzyme converts amyloid beta-protein1-42 to amyloid beta-protein1-40. ACE regulates Abeta1-42/Abeta1-40 ratio in vivo by converting secreted Abeta1-42 to Abeta1-40 and degrading Abetas. The upregulation of ACE activity can be a novel therapeutic strategy for Alzheimers disease |
3.4.15.1 | more |
angiotensin-converting enzyme-2 is a regulatory protein of the renin-angiotensin system. ACE2 interacts with calmodulin and this association down-regulates shedding of the ACE2 ectodomain |
3.4.15.1 | bradykinin + H2O |
bradykinin is a nonapeptide released from high molecular weight kininogen, it exerts its vasodilatory effect mainly by stimulation of B2 receptors |
3.4.15.1 | amyloid beta-peptide(1-40) + H2O |
cleavage at the Asp7-Ser9 bond. Compared with amyloid beta-peptide(1-40), aggregation and cytotoxic effects of the degradation products amyloid beta-peptide(1-7) and amyloid beta-peptide(8-40) are reduced ot virtually absent. The enzyme inhibits aggregation, deposition, and cytotoxicity of amyloid beta-peptide in vitro may affect susceptibility to Alzheimers disease |
3.4.15.1 | more |
complex formation witht e bradykinin B2 receptor |
3.4.15.1 | bradykinin + H2O |
degradation |
3.4.15.1 | angiotensin I + H2O |
enzyme plays a major role in blood pressure regulation |